US 9,457,070 · Application 13/209,349 · Granted Oct 4, 2016
US 9,457,070
Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
Estimated expiration
June 7, 2026
Expired 98 days ago
Earliest effective filing
Jun 7, 2006
+ 20 years
Jun 7, 2026
PTA +404d
Jul 16, 2027
TD cap (US 9,884,096)
Jun 7, 2026
Final
Jun 7, 2026
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- August 12, 2011
- Earliest effective filing
- June 7, 2006
- Issue date
- October 4, 2016
- PTA
- +404 days
- Base expiry (before PTA)
- June 7, 2026
June 7, 2006 + 20 years = June 7, 2026 + 404 PTA days = July 16, 2027
- Continuation-in-part of application 11/916,521, filed Dec 4, 2007
- National stage entry of application PCTUS2006022436, filed Jun 7, 2006
- National stage entry of application PCTUS2006022436, filed Jun 7, 2006
- PRO60/687,850 — Provisional — not used for base term
- PRO60/687,850 — Provisional — not used for base term
- PRO60/687,850 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to June 7, 2026 (earliest expiring referenced patent: US 9,884,096)
US 7,751,402
Could not resolve calculation details
US 9,457,070· Application 13/209,349(from application 13/209,349)Capping patent
Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
- Filing date
- Aug 12, 2011
- Earliest effective filing
- Jun 7, 2006
- Issue date
- Oct 4, 2016
- PTA
- +404 days
- Calculated expiration
- Jul 16, 2027
Continuation-in-part of 11/916,521, filed Dec 4, 2007
National stage entry of PCTUS2006022436, filed Jun 7, 2006
National stage entry of PCTUS2006022436, filed Jun 7, 2006
Jun 7, 2006 + 20y + 404d PTA = Jul 16, 2027
US 9,884,096· Application 14/266,535(from application 14/266,535)Capping patent
Compositions and methods related to graft versus host disease and treatments thereof
- Filing date
- Apr 30, 2014
- Earliest effective filing
- Jun 7, 2006
- Issue date
- Feb 6, 2018
- PTA
- 0 days
- Calculated expiration
- Jun 7, 2026
Continuation of 11/916,521, filed Dec 4, 2007
National stage entry of PCTUS2006022436, filed Jun 7, 2006
National stage entry of PCTUS2006022436, filed Jun 7, 2006
Continuation of 14/063,986, filed Oct 25, 2013
Continuation of 11/916,521, filed Dec 4, 2007
Jun 7, 2006 + 20y = Jun 7, 2026
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 13/209,349 · US 9,457,070
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 9,457,070: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9457070Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.